RT Journal Article
T1 Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge
A1 Soysal, Nurcan
A1 Mariani-Kurkdjian, Patricia
A1 Smail, Yasmine
A1 Liguori, Sandrine
A1 Gouali, Malika
A1 Estelle, Loukiadis
A1 Fach, Patrick
A1 Bruyand, Mathias
A1 Blanco Álvarez, Jorge
A1 Bidet, Philippe
A1 Bonacorsi, Stéphane
AB We describe the epidemiology, clinical features, and molecular characterization of enterohemorrhagic Escherichia coli (EHEC) infections caused by the singular hybrid pathotype O80:H2, and we examine the influence of antibiotics on Shiga toxin production. In France, during 2005–2014, a total of 54 patients were infected with EHEC O80:H2; 91% had hemolytic uremic syndrome. Two patients had invasive infections, and 2 died. All strains carried stx2 (variants stx2a, 2c, or 2d); the rare intimin gene (eae-ξ); and at least 4 genes characteristic of pS88, a plasmid associated with extraintestinal virulence. Similar strains were found in Spain. All isolates belonged to the same clonal group. At subinhibitory concentrations, azithromycin decreased Shiga toxin production significantly, ciprofloxacin increased it substantially, and ceftriaxone had no major effect. Antibiotic combinations that included azithromycin also were tested. EHEC O80:H2, which can induce hemolytic uremic syndrome complicated by bacteremia, is emerging in France. However, azithromycin might effectively combat these infections
PB Centers for Disease Control and Prevention
SN 1080-6040
YR 2016
FD 2016
LK http://hdl.handle.net/10347/16260
UL http://hdl.handle.net/10347/16260
LA eng
NO Soysal, N., Mariani-Kurkdjian, P., Smail, Y., Liguori, S., Gouali, M., Loukiadis, E....Bonacorsi, S. (2016). Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge. Emerging Infectious Diseases, 22(9), 1604-1612. https://dx.doi.org/10.3201/eid2209.160304
NO We thank the French Society of Pediatrics for its support ofthis study.Work in the Labrotorio de referencia de Escherichia coli wasfinanced by grant no. CN2012/303 from Consellería de Cultura,Educación e Ordenación Universitaria (Xunta de Galicia) and theEuropean Regional Development Fund.Dr. Soysal is a pediatrician working in Assistance Publique–Hôpitaux de Paris (AP-HP). Her research domain is pediatricinfections, particularly pathogenicity and therapeuticmanagement of E. coli intestinal infections
DS Minerva
RD 28 abr 2026